Cipher Pharma has a huge upside, says Echelon Wealth

Mar 21 20:03 2019 Print This Article

Look for Cipher Pharmaceuticals (Cipher Pharmaceuticals Stock Quote, Chart TSX:CPH) to break out of its slump in 2019, says Doug Loe of Echelon Wealth Partners. Loe gives a 12-month return of 257 per cent for the stock, saying the specialty pharma company’s pipeline prospects are encouraging. Cipher Pharmaceuticals released its fourth quarter and fiscal 2018 […]

The post Cipher Pharma has a huge upside, says Echelon Wealth appeared first on Cantech Letter.

Read More

About Article Author

Cantech Letter

Founded in 2008 by Nick Waddell, Cantech Letter is an online magazine focusing on Canadian technology. The site has grown into one of the most popular and respected financial sites in Canada, and was described by Canadian Business Magazine as “one of Canada’s premier technology newsletters”. Waddell, who is Senior Editor, is routinely called on by the mainstream media for perspective on Canadian technology, and has been featured on BNN, CTV News Channel, and the CBC program “The Lang and O’Leary Exchange” in addition to mainstream print media such as The Guardian, The International Business Times, The Globe and Mail, Macleans, The Waterloo Record , Canadian Business, Slate, and Business Insider. You can email Nick at nick@cantechletter.com Cantech Letter is focused on those companies listed on the TSX and TSXV Technology, Cleantech and Life Sciences Sectors. Each year we present the Cantech Letter Awards, which honor Canada’s Top Technology Stock and Top Technology Stock Executive.

Related Items

Which pharmaceutical companies have the most drug patents in Colombia?

This chart shows the pharmaceutical companies with the most patents in Colombia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Colombia? appeared first on DrugPatent ...

Week Ahead: Odds Stacked Against A Sustainable Breakout; 11760 Still Remains Important To Watch

The past week was quite eventful for the Indian equity markets. The short 3-day working week saw the benchmark index NIFTY50 marking a fresh high and attempting a breakout. Along with that, it also saw the NIFTY not confirming this breakout, slipping below the all-important 11760 mark once again. ...

Which pharmaceutical companies have the most drug patents in Poland?

This chart shows the pharmaceutical companies with the most patents in Poland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Poland? appeared first on DrugPatentWatc ...

Which pharmaceutical companies have the most drug patents in Australia?

This chart shows the pharmaceutical companies with the most patents in Australia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Australia? appeared first on DrugPate ...

Which pharmaceutical companies have the most drug patents in Argentina?

This chart shows the pharmaceutical companies with the most patents in Argentina. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Argentina? appeared first on DrugPate ...

Antibe Therapeutics has an upside of 352 per cent, Echelon Wealth says

In an update to clients Wednesday, Echelon Wealth Partners analyst Douglas Loe remains bullish on clinical stage drug developer Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart TSXV:ATE), who on Wednesday announced the publication of comprehensive safety data for its naproxen derivative ...

Paradigm Capital launches coverage of Organigram with a Buy

Calling the company’s cultivation techniques paradigm-shifting and its operational efficiencies industry-leading, Paradigm Capital’s Rahul Sarugaser initiated coverage on Tuesday of cannabis company Organigram Holdings (Organigram Holdings Stock Quote, Chart TSX:OGI), starting out with a “Buy ...

ProMetic Life Sciences is not out of the woods yet, Echelon Wealth says

Echelon Wealth Partners analyst Douglas Loe says ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart TSX:PLI) is not out of the woods yet but the drug developer’s recent moves towards revising its capital structure could pare down the company’s financial risk on its core clinical ...

Organigram is undervalued, PI Financial says

Cannabis licensed producer Organigram Holdings (Organigram Holdings Stock Quote, Chart TSXV:OGI) produced its strongest quarter yet, says Jason Zandberg of PI Financial, who in an earnings update to clients Monday reiterated his “Buy” rating and $12.00 target. Moncton, New Brunswick’s Organig ...

Aphria’s future still looks bright, GMP Securities says

GMP Securities analyst Martin Landry says that while quarterly results from Aphria (Aphria Stock Quote, Chart TSX:APHA) were underwhelming, the company should get over its growing pains and flex some of its considerable earnings power. In a research update to clients Tuesday, Landry reiterated his ...